StockDuty ← Dashboard Nov 09, 2026 03:14 AM ET
SignalEU/UK

Novo Nordisk says Wegovy was associated with improvements in several liver-health measures in patients with serious liver disease and BMI below 27. That is a new indication narrative beyond weight los

Wegovy shows liver improvements in some patients, a positive efficacy signal.

What happened: Novo Nordisk (NVO) said Sunday that Wegovy was associated with improvements in several measures of liver health among patients with a serious liver disease who had a body mass index below 27. Why it matters: The findings link Wegovy to liver health benefits in patients below the BMI threshold, extending the reported effects of the weight-loss drug beyond that group.
Novo Nordisk (NVO) said Sunday that Wegovy was associated with improvements in several measures of liver health among patients with a serious liver disease who had a body mass index below 27.
The findings link Wegovy to liver health benefits in patients below the BMI threshold, extending the reported effects of the weight-loss drug beyond that group.
Sources